7Baggers
 published on: 2025-08-31 15:36:57  Newser Sun, 31 Aug 2025 20:36:57 GMT
 published on: 2025-08-30 23:33:10  Newser Sun, 31 Aug 2025 04:33:10 GMT
 published on: 2025-08-30 19:02:33  Newser Sun, 31 Aug 2025 00:02:33 GMT
 published on: 2025-08-29 12:14:58  Newser Fri, 29 Aug 2025 17:14:58 GMT
 published on: 2025-08-28 14:28:51  Newser Thu, 28 Aug 2025 19:28:51 GMT
 published on: 2025-08-28 05:54:37  Newser Thu, 28 Aug 2025 10:54:37 GMT
 published on: 2025-08-28 04:53:15  Newser Thu, 28 Aug 2025 09:53:15 GMT
 lexeo reports q2 loss as costs jump 129%  AOL.com Tue, 26 Aug 2025 17:11:06 GMT
 lexeo therapeutics reports q2 2025 financial results  MSN Sun, 17 Aug 2025 16:35:54 GMT
 published on: 2025-08-16 20:53:05  Newser Sun, 17 Aug 2025 01:53:05 GMT
 Lexeo Therapeutics stock price target lowered to $9 at H.C. Wainwright  Investing.com Fri, 15 Aug 2025 07:00:00 GMT
 lexeo therapeutics appoints new chief financial officer  MSN Fri, 15 Aug 2025 07:00:00 GMT
 lexeo therapeutics reports q2 2025 financial results  TipRanks Fri, 15 Aug 2025 04:40:26 GMT

Lexeo Therapeutics, Inc.
(NASDAQ:LXEO) 

LXEO stock logo

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t...

Founded: 2017
IPO Price: $11 (Nov 13, 2023)
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends